Moberg Pharma

Research interview


Moberg Pharma: Videointervju med vd Peter Wolpert

to view this content. Not a member?
Why should I sign up?
We’ll help you find the best stocks. With an account you gain access to all the research and information needed to improve your stock performance.
No commitment required
A few perks of having an account:
Full access to our research
Full access to our livestreams and video content
Customized research feed based on your preferences
If you have any other questions, don’t hesitate to contact us at or +46 (0)8 545 013 30

I en videointervju med Redeyes analytiker Klas Palin sammanfattar Peter Wolpert, vd på Moberg Pharma, det andra kvartalet som ett av det starkaste någonsin med tillväxt på 27 % och fördubblad lönsamhet.